Letter to the Editor

PEDIATRICS ◽  
1969 ◽  
Vol 43 (5) ◽  
pp. 907-909
Author(s):  
Margaret H. D. Smith
Keyword(s):  
Infectious Disease ◽  
Advisory Committee ◽  
Virus Vaccine ◽  
Mumps Virus ◽  
Immunization Practice ◽  
Surgeon General ◽  
Mumps Vaccine ◽  
The Past ◽  
Letter To The Editor

Thank you for your thoughtful letter about mumps virus vaccine. We have had several letters over the past year from individuals and groups who, like yourselves, have been perturbed about the recommendations for the use of mumps vaccine. Let me first point out that the recommendations for the use of mumps vaccine, which seem to you confused and which others have referred to as "wishywashy," are not those alone of the Committee on Control of Infectious Disease, but that they concur very closely with those of the Advisory Committee on Immunization Practice of the Surgeon General.

Mumps Virus Vaccine

PEDIATRICS ◽  
1969 ◽  
Vol 43 (5) ◽  
pp. 907-907
Author(s):  
Lewis L. Bock
Keyword(s):  
Infectious Diseases ◽  
Advisory Committee ◽  
Virus Vaccine ◽  
Mumps Virus ◽  
Letter To The Editor ◽  
State Board

For several years a number of pediatricians have been on an advisory committee on immunizations to the Montana State Board of Health. At the last meeting I was commissioned to write the Committee on Control of Infectious Diseases regarding the mumps virus vaccine and the recommendations which at that time had not been revised, but which subsequently have been. I am taking the liberty of also sending a copy of this letter to the editor of Pediatrics.

Letter To The Editor

PEDIATRICS ◽  
1996 ◽  
Vol 98 (4) ◽  
pp. 795-796
Author(s):  
Philip Adler
Keyword(s):  
Advisory Committee ◽  
Oral Polio Vaccine ◽  
Immunization Schedule ◽  
Immunization Practice ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine ◽  
Letter To The Editor ◽  
Sequential Schedule

In his argument supporting the Advisory Committee on Immunization Practices-recommended switch to a sequential inactivated polio vaccine/oral polio vaccine (IPV/OPV) immunization schedule (Pediatrics. 1996;98:116-117), Dr Samuel Katz fails to address the enormity of the threat that an untested immunization practice poses to an unprepared public. Dr Katz theorizes that the proposed sequential schedule may reduce the six to eight cases of vaccine-associated paralytic polio that occur each year. Yet no solid proof exists to support this claim.

Persistence of Antibody After Administration of Monovalent and Combined Live Attenuated Measles, Mumps, and Rubella Virus Vaccines

PEDIATRICS ◽  
1978 ◽  
Vol 61 (1) ◽  
pp. 5-11
Author(s):  
Robert E. Weibel ◽  
Eugene B. Buynak ◽  
Arlene A. McLean ◽  
Maurice R. Hilleman
Keyword(s):  
Antibody Titer ◽  
Virus Vaccine ◽  
Rubella Virus ◽  
Natural Infection ◽  
Neutralizing Antibody ◽  
Mumps Virus ◽  
Rubella Vaccine ◽  
Mumps Vaccine ◽  
Antibody Persistence ◽  
Substantial Decline

Hemagglutination-inhibiting antibodies were retained in comparable levels eight years after vaccination with Enders' original Edmonston and more attenuated Moraten (Attenuvax) and Schwarz line measles vaccines. Neutralizing antibody persisted without substantial decline in titer for at least 9.5 years after administration of Jeryl Lynn mumps virus vaccine (Mumpsvax). Antibodies were retained without important decline in children and adults for at least 7.5 and 7 years, respectively, after administration of HPV-77 duck-modified rubella vaccine (Meruvax). The patterns of antibody persistence 7.5 years after administration of combined measles-mumps-rubella (M-M-R) and mumps-rubella (Biavax) vaccines, 6 years after administration of measles-rubella vaccine (M-R-VAX), and 4 years after administration of measles-mumps vaccine (M-M-VAX) were the same as for the monovalent vaccines, indicating no alteration in the retention of immunity. Subclinical reinfection evidenced by increase in homologous antibody titer was observed to follow vaccination the same as occurs after natural infection.

Current Status of Mumps and Mumps Vaccine in the United States

PEDIATRICS ◽  
1978 ◽  
Vol 62 (6) ◽  
pp. 965-969
Author(s):  
Gregory F. Hayden ◽  
Stephen R. Preblud ◽  
Walter A. Orenstein ◽  
J. Lyle Conrad
Keyword(s):  
Public Health ◽  
United States ◽  
Virus Vaccine ◽  
The United States ◽  
Mumps Virus ◽  
Current Status ◽  
Live Virus ◽  
Control Programs ◽  
Mumps Vaccine ◽  
Low Levels

Reported mumps in the United States has declined to all-time low levels following the increasingly widespread use of mumps-virus vaccine. Mumps vaccine has proven safe and effective. Its incorporation into combined live-virus vaccines, especially measles-mumps-rubella, has made mumps vaccination a practical and economically feasible component of routine immunization activities. Because of the favorable experience to date with mumps vaccine and the associated drop in mumps morbidity and mortality, mumps control programs likely will receive increasing public health attention in the coming years.

scholarly journals Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

2020 ◽  
Vol 17 (5) ◽  
pp. 1686 ◽  
Author(s):  
Shih-Bin Su ◽  
Hsiao-Liang Chang ◽  
Kow-Tong Chen
Keyword(s):  
Infectious Disease ◽  
English Language ◽  
Web Of Science ◽  
Vaccine Development ◽  
Developed Countries ◽  
Mumps Virus ◽  
Current Status ◽  
Mmr Vaccine ◽  
Public Authorities ◽  
Mumps Vaccine

Mumps is an important childhood infectious disease caused by mumps virus (MuV). We reviewed the epidemiology, pathogenesis, and vaccine development of mumps. Previous studies were identified using the key words “mumps” and “epidemiology”, “pathogenesis” or “vaccine” in MEDLINE, PubMed, Embase, Web of Science, and Google Scholar. We excluded the articles that were not published in the English language, manuscripts without abstracts, and opinion articles from the review. The number of cases caused by MuV decreased steeply after the introduction of the mumps vaccine worldwide. In recent years, a global resurgence of mumps cases in developed countries and cases of aseptic meningitis caused by some mumps vaccine strains have renewed the importance of MuV infection worldwide. The performance of mumps vaccination has become an important issue for controlling mumps infections. Vaccine development and routine vaccination are still effective measures to globally reduce the incidence of mumps infections. During outbreaks, a third of MMR vaccine is recommended for groups of persons determined by public authorities.

Jeryl Lynn Strain Live Attenuated Mumps Virus Vaccine

JAMA ◽  
1968 ◽  
Vol 203 (1) ◽  
pp. 14 ◽  
Author(s):  
Robert E. Weibel
Keyword(s):  
Virus Vaccine ◽  
Mumps Virus

scholarly journals Matched Case-Control Study of Effectiveness of Live, Attenuated S79 Mumps Virus Vaccine against Clinical Mumps

2008 ◽  
Vol 15 (9) ◽  
pp. 1425-1428 ◽  
Author(s):  
Chuanxi Fu ◽  
Jianhua Liang ◽  
Ming Wang
Keyword(s):  
Virus Vaccine ◽  
Case Control Study ◽  
Early Adulthood ◽  
Mumps Virus ◽  
Control And Prevention ◽  
Matched Case ◽  
Pediatric Use ◽  
Computerized System ◽  
Matched Case Control Study ◽  
Control Study

ABSTRACT Mumps virus infection is a potentially serious viral infection of childhood and early adulthood. In China, live, attenuated S79 mumps virus vaccine has been licensed for pediatric use since 1990. There has been no assessment of its efficacy. Thus, the objective of this study was to determine the effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Cases were selected from the China Information System for Disease Control and Prevention during September 2004 to March 2005. Each case was matched to a control by gender, age, and area of residency. In all, 469 cases and 469 controls were enrolled in the study. Vaccination information was obtained from the Children's EPI Administrative Computerized System. Vaccine effectiveness (VE) was calculated for one or two doses of S79 vaccine, with 95% confidence intervals (CI). VE of mumps virus vaccine for one dose versus none was protection of 86.0% (95% CI, 77.2% to 91.5%) of recipients, and VE was much higher in the first 4 years than in the 5 to 12 years after vaccination. The S79 vaccine can effectively prevent clinical mumps, and a second dose of mumps virus vaccine is necessary for the protection of children in China.

Sign in / Sign up

Export Citation Format

Share Document